The Sciety syndicate invests in Synartro, which uses existing drugs with proven efficacy to develop an improved drug treatment of knee osteoarthritis. The new capital will be used to complete the pre-clinical development. The company plans to go public to raise capital for phase 1 clinical trials in 2021. Synartro’s
Sciety talks with Pavan Asalapuram, co-founder of EMPE Diagnostics, a company that develops rapid diagnostic solutions for infectious diseases, with a special focus on tuberculosis––a major public health problem in big parts of the world. EMPE’s test can within two hours identify whether a person has TB and whether it
The Sciety investment syndicate recently made an investment of 9.1 million SEK in the company Cavis Technologies, which has developed Wirecath®––a patent-pending product for the diagnosis of coronary heart diseases. The new capital will be used to establish sales on the European market. “Only in Europe, over 1.5 million people
Today, Sciety wants to pay attention to World TB Day, which aims to highlight the extensive health, social and economic consequences of tuberculosis. Tuberculosis is a contagious infectious disease that primarily affects the lungs but also other organs. It is an airborne disease that spreads when a person with tuberculosis
One of the most common causes of death in the world comes from diseases of the coronary arteries, the heart’s own blood vessels. Coronary artery disease occurs through constriction of the coronary arteries that leads to a pressure drop which can cause heart attack and stroke. Diseases of the coronary
Sciety invests SEK 35 million in the company Elypta, which is developing a new method for early cancer diagnosis. The Sciety network together with the Swedish venture capital fund Industrifonden, Chalmers Ventures and several of the company’s existing owners took part in the capitalization. The new capital of a total